Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 36

1.

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.

Moorthy VS, Pinder M, Reece WH, Watkins K, Atabani S, Hannan C, Bojang K, McAdam KP, Schneider J, Gilbert S, Hill AV.

J Infect Dis. 2003 Oct 15;188(8):1239-44. Epub 2003 Sep 30.

PMID:
14551895
2.

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant.

Garçon N, Heppner DG, Cohen J.

Expert Rev Vaccines. 2003 Apr;2(2):231-8. Review.

PMID:
12899574
3.

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.

McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV.

Nat Med. 2003 Jun;9(6):729-35. Epub 2003 May 25.

PMID:
12766765
4.

Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine.

Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA.

Mol Biochem Parasitol. 2003 May;128(2):195-204.

PMID:
12742586
5.

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.

Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA, Miller LH, Stowers AW.

Infect Immun. 2002 Dec;70(12):6948-60.

6.
7.

Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria.

Arévalo-Herrera M, Valencia AZ, Vergara J, Bonelo A, Fleischhauer K, González JM, Restrepo JC, López JA, Valmori D, Corradin G, Herrera S.

Parasite Immunol. 2002 Mar;24(3):161-9.

8.

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites.

Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL.

J Infect Dis. 2002 Apr 15;185(8):1155-64. Epub 2002 Apr 1.

PMID:
11930326
9.

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.

Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP.

J Infect Dis. 2002 Mar 15;185(6):820-7. Epub 2002 Feb 14.

PMID:
11920300
10.

Towards a blood-stage vaccine for malaria: are we following all the leads?

Good MF.

Nat Rev Immunol. 2001 Nov;1(2):117-25. Review.

PMID:
11905819
11.

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T; RTS, S Malaria Vaccine Trial Team.

Lancet. 2001 Dec 8;358(9297):1927-34.

PMID:
11747915
12.

Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate.

Milich DR, Hughes J, Jones J, Sällberg M, Phillips TR.

Vaccine. 2001 Dec 12;20(5-6):771-88.

PMID:
11738741
13.

A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies.

López JA, Weilenman C, Audran R, Roggero MA, Bonelo A, Tiercy JM, Spertini F, Corradin G.

Eur J Immunol. 2001 Jul;31(7):1989-98. Erratum in: Eur J Immunol 2001 Sep;31(9):2839.

14.

Specificity of the protective antibody response to apical membrane antigen 1.

Hodder AN, Crewther PE, Anders RF.

Infect Immun. 2001 May;69(5):3286-94.

15.

Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate.

Gozar MM, Muratova O, Keister DB, Kensil CR, Price VL, Kaslow DC.

Exp Parasitol. 2001 Feb;97(2):61-9.

PMID:
11281702
16.

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR; RTS,S Malaria Vaccine Evaluation Group.

J Infect Dis. 2001 Feb 15;183(4):640-7. Epub 2001 Jan 24.

PMID:
11170991
17.

Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.

Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, BenMohamed L, Slierendregt B, Eling W, Van Belkum A, Dubreuil G, Meis JF, Guérin-Marchand C, Cayphas S, Cohen J, Gras-Masse H, Druilhe P.

Nat Med. 2000 Nov;6(11):1258-63. Erratum in: Nat Med 2000 Dec;6(12):1412. Mohamed LB [corrected to BenMohamed L].

PMID:
11062538
18.
19.

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.

Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Hoffman SL.

Vaccine. 2000 Mar 17;18(18):1893-901.

PMID:
10699338
20.

Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria.

Holder AA, Guevara Patiño JA, Uthaipibull C, Syed SE, Ling IT, Scott-Finnigan T, Blackman MJ.

Parassitologia. 1999 Sep;41(1-3):409-14. Review.

PMID:
10697894

Supplemental Content

Support Center